Christopher Christie
Insider
First SEC filing: Sept. 20, 2019 · Latest: June 12, 2026
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 10, 2026 | PCRX | A | 10,891 | · | · | 10,891 Direct | · | Acquired | (price as of 2026-10-05) |
| June 10, 2026 | PCRX | A | 6,405 | · | · | 23,059 Direct | +38.46% | Acquired | (price as of 2026-10-05) |
| June 11, 2025 | PCRX | A | 6,163 | · | · | 16,654 Direct | +58.75% | Acquired | (price as of 2026-10-05) |
| June 11, 2025 | PCRX | A | 11,279 | · | · | 11,279 Direct | · | Acquired | (price as of 2026-10-05) |
| June 12, 2024 | PCRX | A | 5,230 | · | · | 10,491 Direct | +99.41% | Acquired | (price as of 2026-10-05) |
| June 12, 2024 | PCRX | A | 12,179 | · | · | 12,179 Direct | · | Acquired | (price as of 2026-10-05) |
| June 14, 2023 | PCRX | A | 12,925 | · | · | 12,925 Direct | · | Acquired | (price as of 2026-10-05) |
| June 14, 2023 | PCRX | A | 1,775 | · | · | 5,261 Direct | +50.92% | Acquired | (price as of 2026-10-05) |
| June 8, 2022 | PCRX | A | 8,225 | · | · | 8,225 Direct | · | Acquired | (price as of 2026-10-05) |
| June 8, 2022 | PCRX | A | 1,160 | · | · | 3,486 Direct | +49.87% | Acquired | (price as of 2026-10-05) |
| June 9, 2021 | PCRX | A | 1,066 | · | · | 2,326 Direct | +84.60% | Acquired | (price as of 2026-10-05) |
| June 9, 2021 | PCRX | A | 7,626 | · | · | 7,626 Direct | · | Acquired | (price as of 2026-10-05) |
| June 9, 2020 | PCRX | A | 8,027 | · | · | 8,027 Direct | · | Acquired | (price as of 2026-10-05) |
| June 9, 2020 | PCRX | A | 1,260 | · | · | 1,260 Direct | · | Acquired | (price as of 2026-10-05) |
| Sept. 18, 2019 | PCRX | A | 19,919 | · | · | 19,919 Direct | · | Acquired | (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 10, 2026 | PCRX | Stock Option (Right to Buy) | Common Stock | $23.42 | June 10, 2036 | 10,891 | Acquired |
| June 11, 2025 | PCRX | Stock Option (Right to Buy) | Common Stock | $24.34 | June 11, 2035 | 11,279 | Acquired |
| June 12, 2024 | PCRX | Stock Option (Right to Buy) | Common Stock | $28.68 | June 12, 2034 | 12,179 | Acquired |
| June 14, 2023 | PCRX | Stock Option (Right to Buy) | Common Stock | $38.74 | June 14, 2033 | 12,925 | Acquired |
| June 8, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $59.39 | June 8, 2032 | 8,225 | Acquired |
| June 9, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $60.96 | June 9, 2031 | 7,626 | Acquired |
| June 9, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock | $47.65 | June 9, 2030 | 8,027 | Acquired |
| Sept. 18, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock | $37.16 | Sept. 18, 2029 | 19,919 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.